Merck to spin off women's health and biosimilar drugs, focus on Keytruda

Merck& Co Inc said on Wednesday it intends to spin off its women's health, biosimilar drugs and older products into a new publicly traded company, a move that will allow the company to focus on growth drivers like cancer drug Keytruda and vaccines.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news